274 related articles for article (PubMed ID: 25275313)
1. Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors.
Fichna J; Bawa M; Thakur GA; Tichkule R; Makriyannis A; McCafferty DM; Sharkey KA; Storr M
PLoS One; 2014; 9(10):e109115. PubMed ID: 25275313
[TBL] [Abstract][Full Text] [Related]
2. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.
Schicho R; Bashashati M; Bawa M; McHugh D; Saur D; Hu HM; Zimmer A; Lutz B; Mackie K; Bradshaw HB; McCafferty DM; Sharkey KA; Storr M
Inflamm Bowel Dis; 2011 Aug; 17(8):1651-64. PubMed ID: 21744421
[TBL] [Abstract][Full Text] [Related]
3. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
[TBL] [Abstract][Full Text] [Related]
4. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis.
Storr MA; Keenan CM; Zhang H; Patel KD; Makriyannis A; Sharkey KA
Inflamm Bowel Dis; 2009 Nov; 15(11):1678-85. PubMed ID: 19408320
[TBL] [Abstract][Full Text] [Related]
5. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner.
Keenan CM; Storr MA; Thakur GA; Wood JT; Wager-Miller J; Straiker A; Eno MR; Nikas SP; Bashashati M; Hu H; Mackie K; Makriyannis A; Sharkey KA
Br J Pharmacol; 2015 May; 172(9):2406-18. PubMed ID: 25572435
[TBL] [Abstract][Full Text] [Related]
6. Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors.
Sałaga M; Polepally PR; Zakrzewski PK; Cygankiewicz A; Sobczak M; Kordek R; Zjawiony JK; Krajewska WM; Fichna J
Biochem Pharmacol; 2014 Dec; 92(4):618-26. PubMed ID: 25265540
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor.
Buckley NE; McCoy KL; Mezey E; Bonner T; Zimmer A; Felder CC; Glass M; Zimmer A
Eur J Pharmacol; 2000 May; 396(2-3):141-9. PubMed ID: 10822068
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
de Lago E; Moreno-Martet M; Cabranes A; Ramos JA; Fernández-Ruiz J
Neuropharmacology; 2012 Jun; 62(7):2299-308. PubMed ID: 22342378
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids.
Grotenhermen F
Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):507-30. PubMed ID: 16266285
[TBL] [Abstract][Full Text] [Related]
10. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.
Abalo R; Chen C; Vera G; Fichna J; Thakur GA; López-Pérez AE; Makriyannis A; Martín-Fontelles MI; Storr M
Neurogastroenterol Motil; 2015 Dec; 27(12):1721-35. PubMed ID: 26387676
[TBL] [Abstract][Full Text] [Related]
11. Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms.
Michler T; Storr M; Kramer J; Ochs S; Malo A; Reu S; Göke B; Schäfer C
Am J Physiol Gastrointest Liver Physiol; 2013 Jan; 304(2):G181-92. PubMed ID: 23139224
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
Wagner JA; Járai Z; Bátkai S; Kunos G
Eur J Pharmacol; 2001 Jul; 423(2-3):203-10. PubMed ID: 11448486
[TBL] [Abstract][Full Text] [Related]
13. The GPR55 antagonist CID16020046 protects against intestinal inflammation.
Stančić A; Jandl K; Hasenöhrl C; Reichmann F; Marsche G; Schuligoi R; Heinemann A; Storr M; Schicho R
Neurogastroenterol Motil; 2015 Oct; 27(10):1432-45. PubMed ID: 26227635
[TBL] [Abstract][Full Text] [Related]
14. The anti-nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex.
Limebeer CL; Rock EM; Mechoulam R; Parker LA
Br J Pharmacol; 2012 Nov; 167(5):1126-36. PubMed ID: 22671779
[TBL] [Abstract][Full Text] [Related]
15. The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.
Kinsey SG; Mahadevan A; Zhao B; Sun H; Naidu PS; Razdan RK; Selley DE; Imad Damaj M; Lichtman AH
Neuropharmacology; 2011; 60(2-3):244-51. PubMed ID: 20849866
[TBL] [Abstract][Full Text] [Related]
16. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation.
Alhouayek M; Lambert DM; Delzenne NM; Cani PD; Muccioli GG
FASEB J; 2011 Aug; 25(8):2711-21. PubMed ID: 21551239
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice.
DeSanty KP; Dar MS
Pharmacol Biochem Behav; 2001; 69(1-2):251-9. PubMed ID: 11420093
[TBL] [Abstract][Full Text] [Related]
18. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure.
Szczesniak AM; Maor Y; Robertson H; Hung O; Kelly ME
J Ocul Pharmacol Ther; 2011 Oct; 27(5):427-35. PubMed ID: 21770780
[TBL] [Abstract][Full Text] [Related]
19. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures.
Molina-Holgado F; Molina-Holgado E; Guaza C; Rothwell NJ
J Neurosci Res; 2002 Mar; 67(6):829-36. PubMed ID: 11891798
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability.
Alhamoruni A; Lee AC; Wright KL; Larvin M; O'Sullivan SE
J Pharmacol Exp Ther; 2010 Oct; 335(1):92-102. PubMed ID: 20592049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
